How the Body's First Defense Cells Recognize Tuberculosis
Innate sensing of M. tuberculosis by alveolar macrophages
['FUNDING_R01'] · UNIVERSITY OF MASSACHUSETTS AMHERST · NIH-11170590
This work explores how the very first immune cells in our lungs react to tuberculosis bacteria, aiming to find new ways to fight this infection.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MASSACHUSETTS AMHERST (nih funded) |
| Locations | 1 site (HADLEY, UNITED STATES) |
| Trial ID | NIH-11170590 on ClinicalTrials.gov |
What this research studies
Tuberculosis (TB) remains a major global health challenge, and we urgently need better treatments and vaccines. This project focuses on alveolar macrophages, which are the first immune cells in your lungs to encounter the tuberculosis bacteria after you breathe them in. We want to understand how these cells recognize the bacteria and what signals they send, or fail to send, to the rest of the immune system. By understanding these early interactions, we hope to uncover new strategies to help the body fight off TB more effectively from the very beginning.
Who could benefit from this research
Good fit: This foundational research is relevant to adults aged 21 and older who are susceptible to or have been exposed to tuberculosis, including those who have received the BCG vaccine.
Not a fit: Patients seeking immediate treatment or direct clinical intervention for active tuberculosis will not directly benefit from this basic science research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new drugs, diagnostics, or vaccines that target the early stages of tuberculosis infection.
How similar studies have performed: This project builds upon previous findings that have shown how lung immune cells respond to tuberculosis, indicating a foundation of prior successful work.
Where this research is happening
HADLEY, UNITED STATES
- UNIVERSITY OF MASSACHUSETTS AMHERST — HADLEY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROTHCHILD, ALISSA CHEN — UNIVERSITY OF MASSACHUSETTS AMHERST
- Study coordinator: ROTHCHILD, ALISSA CHEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.